When Will OpenEvidence IPO? A $15 Billion Valuation, Still No Filing

By Segmara Research · Published · Updated

Start from $25 → · Request OpenEvidence Allocation → · Stripe checkout (Card, Apple Pay, Link · no password · terms).

Just researching? Get free OpenEvidence mark alerts by email

Free tracker, email only. No card, no documents. Or start from $25 on Stripe →

As of September 27, 2026, OpenEvidence has not filed a registration statement, and no Form S-1 appears on SEC EDGAR, which covers only US filings. Crunchbase News reported on September 2, 2026 that OpenEvidence was one of eight startups it judged to have a 'probable' chance of an IPO within six months, citing CEO Daniel Nadler's view that foundation-model companies such as OpenAI and Anthropic need to go public before application-layer companies like OpenEvidence can follow. On September 24, 2026, Business Insider reported that OpenEvidence had raised $250 million from hospital systems and Andreessen Horowitz at a $15 billion valuation, up from the $12 billion it reached in a January 2026 round. Separately, on September 22, 2026, Reuters reported that Anthropic and OpenEvidence had announced a partnership to expand AI-powered clinical decision support to physicians in dozens of low- and middle-income countries. None of this reporting is an IPO filing or a confirmed date. Track SEC EDGAR and OpenEvidence's own statements directly, not secondary chatter.

Pre-IPO Allocation: Start OpenEvidence from $25 via Stripe or explore 140+ live pre-IPO listings →

Educational pre-IPO guide. Share allocations and secondary transactions are subject to eligibility and private settlement terms.

Start OpenEvidence from $25 →

Key points

A 'probable' rating, not a filing

Crunchbase News reported on September 2, 2026 that OpenEvidence was one of eight startups it judged to have a 'probable' chance of going public within six months. The assessment was tied to comments from CEO Daniel Nadler, whom Crunchbase said believes foundation-model companies such as OpenAI and Anthropic have to complete their own public listings before application-layer companies like OpenEvidence follow onto the market.

That is an analyst's forward-looking read, not a registration statement. As of September 27, 2026, no Form S-1 or F-1 for OpenEvidence appears on SEC EDGAR, which covers only US filings, and OpenEvidence has not announced a listing date.

The valuation has moved fast

Business Insider reported on September 24, 2026 that OpenEvidence raised $250 million from hospital systems and Andreessen Horowitz at a valuation of $15 billion. That is up from the $12 billion valuation it reached in a January 2026 round, according to the same report.

Neither figure is tied to a public offering price; both describe private funding rounds.

A partnership with one of the foundation-model companies it's waiting on

On September 22, 2026, Reuters reported that Anthropic and OpenEvidence had announced a partnership to expand AI-powered clinical decision support to physicians in dozens of low- and middle-income countries.

The deal links OpenEvidence to Anthropic, one of the foundation-model companies that CEO Daniel Nadler said, per Crunchbase News, needs to go public before application-layer companies like OpenEvidence can follow. The partnership itself is a product and distribution deal, not an IPO step.

Private-share data lens

Public round-by-round marks are incomplete for this company. Segmara shows the listing mark and keeps the seed-to-IPO analysis focused on verifiable funding, tender, or secondary signals.

Segmara markNo indicative price yet

Indicative listing context

StageDateValuation / price signalWhy it matters
Seed / earlyPrivateNot reliably publicDo not invent a seed price when the source set is thin.
Growth roundsPrivateCompany and market sources varyUse public sources and official company releases.
Segmara listingCurrentNo indicative price yetIndicative reference only, not a quote or an offer.
IPO statusCurrentNo public ticker shown hereWatch official company releases and the free Segmara IPO calendar.

Seed-to-IPO path

Illustrative completeness map. Longer bars mean stronger public data or more useful current pricing context, not lower risk.

Early data22%
Growth data46%
Segmara mark68%
IPO/public18%
Start OpenEvidence from $25 →

AI-ready data summary

A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.

MetricValueContext
Canonical route/blog/when-will-openevidence-ipoStable URL path for AI and search extraction.
Article titleWhen Will OpenEvidence IPO? A $15 Billion Valuation, Still No FilingMain page topic.
Attached public sources3Number of citation links rendered at the bottom of the article.
Segmara listed companies148Live private-company listings in the public catalogue.
Priced listings37Catalogue listings with visible indicative or direct marks.
Listings without an indicative price111Catalogue listings where a public price is intentionally not invented.
CompanyOpenEvidenceNamed company covered by this page.
Symbol labelOPEVSegmara display symbol; not a public stock ticker unless separately stated.
SectorHealthcare AICatalogue sector used for comparison and internal linking.
Listing structureRequestHow the listing is categorized on Segmara.
Segmara markNo indicative price yetVisible listing mark, or no indicative price yet.
Sector peer count2Number of live Segmara listings in Healthcare AI.
Structure peer count111Number of live Segmara listings categorized as Request.
StageTimingPrice / valuation signalInterpretation
FormationPrivateEarly ownershipThe first value creation happens before ordinary public-market access.
Growth roundsPrivateInstitutional repricingLater rounds and tenders create the price history buyers study.
Segmara listingCurrentNo indicative price yetIndicative reference only, not a quote or an offer.
Exit pathFutureIPO, tender, acquisition, or continued private statusLiquidity timing remains company-specific.
Chart metricScoreInterpretation
Start OpenEvidence from $25 →

Analytical lens

Search intent

Searches like 'When Will OpenEvidence IPO? A $15 Billion Valuation, Still No Filing' are research questions: what a filing or a company statement confirms, what has only been reported, and what is still unknown.

What counts as a listing step

For an IPO, the primary record is a registration statement filed with the securities regulator of the listing market, such as an S-1 or F-1 on SEC EDGAR for a US listing. Funding rounds, valuations and secondary-market prices are context, not listing steps.

Segmara role

Segmara takes reviewed pre-IPO allocation requests funded by Stripe USD credits from $25 ($1.00 starter credit); no allocation is guaranteed. It also publishes dated indicative reference marks across 140+ private companies. Nothing on this page is investment advice.

How pre-IPO share access works

Standard Segmara allocation path

1. SearchStart with the company or pre-IPO question
2. ListingReview indicative mark and structure context
3. CheckoutFund from $25 ($1 starter credit) via Stripe, no password
4. ReviewEach request is reviewed in your dashboard; no allocation is guaranteed

What happens after payment

Indicative mark & listing selectionPublic
No-password StripeFrom $25 / $1 credit
Share allocation requestDirect
Transfer & settlement termsReviewed, not guaranteed
Start OpenEvidence from $25 →

Key takeaways

Risk notes

Public source links

PRE-IPO ALLOCATION

Request OpenEvidence pre-IPO shares

Start from $25 in USD portfolio credits via Stripe (no password required) and request a pre-IPO share allocation in OpenEvidence.

Start OpenEvidence from $25 →

1-unit requests under $20: Aalo ($1.00) · ID.me ($1.40) · Chainalysis ($6.20) · Precision ($8.18) · Scale AI ($8.78) · Huntress ($19.03)

Explore all pre-IPO listingsFund portfolio credits

Questions

Can investors request private-company shares on Segmara?

Yes. Start from $25 ($1.00 starter credit available) in USD portfolio credits via Stripe with no password required, or select a listing across 140+ private companies on Segmara to submit a pre-IPO share allocation request.

Why was this market historically hard for individual investors to reach?

Private-company share access has often moved through private equity firms, venture funds, insiders, institutions, and relationship-driven secondary networks. Segmara makes the starting point simpler: browse 140+ named private-company listings, fund USD credits via Stripe from $25 ($1.00 starter credit), and request share allocations with no password wall.

What is the easiest next step?

Start from $25 ($1.00 starter credit available) via instant Stripe checkout (Card, Apple Pay, Link, no password required), or browse Segmara's live pre-IPO listings to select your target company.

Has OpenEvidence confirmed an IPO date?

No. As of September 27, 2026, no S-1 or F-1 has been filed on SEC EDGAR. Crunchbase News rated OpenEvidence a 'probable' IPO candidate within six months on September 2, 2026, but that is an analyst assessment, not a company-confirmed date.

What is OpenEvidence worth?

Business Insider reported on September 24, 2026 that OpenEvidence raised $250 million from hospital systems and Andreessen Horowitz at a $15 billion valuation, up from the $12 billion it reached in a January 2026 round.

Why does OpenEvidence's IPO timing depend on OpenAI and Anthropic?

Crunchbase News reported on September 2, 2026 that CEO Daniel Nadler believes foundation-model companies such as OpenAI and Anthropic need to go public before application-layer companies like OpenEvidence can follow, part of why Crunchbase called an OpenEvidence IPO 'probable' within six months rather than confirmed.

Can I buy OpenEvidence shares before the IPO?

Not through a public exchange. OpenEvidence is a private company, and Segmara does not sell, broker, or arrange purchases of OpenEvidence shares.

Pre-IPO Allocation

Request OpenEvidence shares on Segmara.

Start from $25 ($1 starter credit available) via Stripe with no password required, fund USD portfolio credits, and request a pre-IPO allocation in OpenEvidence.

Request OpenEvidence Allocation →

1-unit requests under $20: Aalo ($1.00) · ID.me ($1.40) · Chainalysis ($6.20) · Precision ($8.18) · Scale AI ($8.78) · Huntress ($19.03)

Explore 140+ pre-IPO listings · Custom credit amount

Start OpenEvidence from $25 →